Identification of Biological Markers of Liver X Receptor (LXR) Activation at the Cell Surface of Human Monocytes

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Rébé, Cédric ^a,b   Filomenko, Rodolphe ^a   Raveneau, Magalie ^a   Chevriaux, Angélique ^a,b   Ishibashi, Minako ^a   Lagrost, Laurent ^a,c   Junien, Jean Louis ^a   Gambert, Philippe ^a,c   Masson, David ^a,c  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; BIOLOGICAL MARKER; CD226 ANTIGEN; CD244 ANTIGEN; CD82 ANTIGEN; CYCLOPHILIN A; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; MESSENGER RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BLOOD CELL; CELL DIFFERENTIATION; CELL SURFACE; CONTROLLED STUDY; DOSE RESPONSE; FLOW CYTOMETRY; FOAM CELL; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MACROPHAGE; MICROARRAY ANALYSIS; MONOCYTE; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ANTIGENS, CD; BIOLOGICAL MARKERS; CELL MEMBRANE; CHOLESTEROL; FOAM CELLS; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYDROCARBONS, FLUORINATED; MACROPHAGES; MONOCYTES; ORPHAN NUCLEAR RECEPTORS; RNA, MESSENGER; SULFONAMIDES;

EID: 84869796113     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048738     Document Type: Article

References (33)

1. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ, (2001) Nuclear receptors and lipid physiology: opening the X-files. Science 294: 1866-1870.
2. Zelcer N, Tontonoz P, (2006) Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 116: 607-614.
3. Calkin AC, Tontonoz P, (2012) Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol.
4. Viennois E, Mouzat K, Dufour J, Morel L, Lobaccaro JM, et al. (2012) Selective liver X receptor modulators (SLiMs): what use in human health? Mol Cell Endocrinol 351: 129-141.
5. Calkin AC, Tontonoz P, (2010) Liver x receptor signaling pathways and atherosclerosis. Arterioscler Thromb Vasc Biol 30: 1513-1518.
6. Naik SU, Wang X, Da Silva JS, Jaye M, Macphee CH, et al. (2006) Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 113: 90-97.
7. Costet P, Luo Y, Wang N, Tall AR, (2000) Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem 275: 28240-28245.
8. Luo Y, Tall AR, (2000) Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest 105: 513-520.
9. Lehmann JM, Kliewer SA, Moore LB, Smith-Oliver TA, Oliver BB, et al. (1997) Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 272: 3137-3140.
10. Laffitte BA, Joseph SB, Chen M, Castrillo A, Repa J, et al. (2003) The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol Cell Biol 23: 2182-2191.
11. Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, et al. (2002) Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem 277: 18793-18800.
12. Wang N, Ranalletta M, Matsuura F, Peng F, Tall AR, (2006) LXR-induced redistribution of ABCG1 to plasma membrane in macrophages enhances cholesterol mass efflux to HDL. Arterioscler Thromb Vasc Biol 26: 1310-1316.
13. Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, et al. (2002) Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A 99: 7604-7609.
14. Terasaka N, Hiroshima A, Koieyama T, Ubukata N, Morikawa Y, et al. (2003) T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett 536: 6-11.
15. Quinet EM, Basso MD, Halpern AR, Yates DW, Steffan RJ, et al. (2009) LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J Lipid Res 50: 2358-2370.
16. Verschuren L, de Vries-van der Weij J, Zadelaar S, Kleemann R, Kooistra T, (2009) LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms. J Lipid Res 50: 301-311.
17. Tangirala RK, Bischoff ED, Joseph SB, Wagner BL, Walczak R, et al. (2002) Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci U S A 99: 11896-11901.
18. Levin N, Bischoff ED, Daige CL, Thomas D, Vu CT, et al. (2005) Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler Thromb Vasc Biol 25: 135-142.
19. Zhang Y, Breevoort SR, Angdisen J, Fu MG, Schmidt DR, et al. (2012) Liver LXR alpha expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice. Journal of Clinical Investigation 122: 1688-1699.
20. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, et al. (2000) Role of LXRs in control of lipogenesis. Genes Dev 14: 2831-2838.
21. Cao G, Beyer TP, Yang XP, Schmidt RJ, Zhang Y, et al. (2002) Phospholipid transfer protein is regulated by liver X receptors in vivo. J Biol Chem 277: 39561-39565.
22. Honzumi S, Shima A, Hiroshima A, Koieyama T, Terasaka N, Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits. Biochim Biophys Acta 1811: 1136-1145.
23. Groot PH, Pearce NJ, Yates JW, Stocker C, Sauermelch C, et al. (2005) Synthetic LXR agonists increase LDL in CETP species. J Lipid Res 46: 2182-2191.
24. Masson D, Staels B, Gautier T, Desrumaux C, Athias A, et al. (2004) Cholesteryl ester transfer protein modulates the effect of liver X receptor agonists on cholesterol transport and excretion in the mouse. J Lipid Res 45: 543-550.
25. Rebe C, Raveneau M, Chevriaux A, Lakomy D, Sberna AL, et al. (2009) Induction of transglutaminase 2 by a liver X receptor/retinoic acid receptor alpha pathway increases the clearance of apoptotic cells by human macrophages. Circ Res 105: 393-401.
26. DiBlasio-Smith EA, Arai M, Quinet EM, Evans MJ, Kornaga T, et al. (2008) Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells. J Transl Med 6: 59.
27. Spencer TA, Li D, Russel JS, Collins JL, Bledsoe RK, et al. (2001) Pharmacophore analysis of the nuclear oxysterol receptor LXRalpha. J Med Chem 44: 886-897.
28. Kase ET, Thoresen GH, Westerlund S, Hojlund K, Rustan AC, et al. (2007) Liver X receptor antagonist reduces lipid formation and increases glucose metabolism in myotubes from lean, obese and type 2 diabetic individuals. Diabetologia 50: 2171-2180.
29. Miao B, Zondlo S, Gibbs S, Cromley D, Hosagrahara VP, et al. (2004) Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. J Lipid Res 45: 1410-1417.
30. Tsai YC, Weissman AM, (2011) Dissecting the diverse functions of the metastasis suppressor CD82/KAI1. FEBS Lett 585: 3166-3173.
31. Reymond N, Imbert AM, Devilard E, Fabre S, Chabannon C, et al. (2004) DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J Exp Med 199: 1331-1341.
32. Cannons JL, Tangye SG, Schwartzberg PL, (2011) SLAM family receptors and SAP adaptors in immunity. Annu Rev Immunol 29: 665-705.
33. Nakajima H, Cella M, Langen H, Friedlein A, Colonna M, (1999) Activating interactions in human NK cell recognition: the role of 2B4-CD48. Eur J Immunol 29: 1676-1683.